What happened
On September 4, China Resources Sanjiu announced it had hosted investors participating in its 2026 semi-annual performance briefing on the same day.
The company was represented by Chairman Qiu Huawei, President Wu Wenduo, CFO and Board Secretary Xing Jian, Vice Presidents Wang Liang and Wang Ke, and independent director Sun Jian.
During the session, management responded to questions about R&D innovation, revealing that R&D investment reached 731 million yuan in the first half of 2026.
Why it matters
The disclosed R&D figure underscores the company's stated 'innovation plus brand' dual-drive strategy, signaling a continued financial commitment to building its pipeline.
Management's focus on therapeutic areas such as digestive metabolism, cardiovascular and cerebrovascular, cold and respiratory, and neuropsychiatry indicates where future product growth may be concentrated.
Investor attention to R&D outcomes suggests the market is closely monitoring how these investments translate into new products and long-term competitiveness.
Key facts
China Resources Sanjiu hosted investor research on September 4, 2026, at its 2026 semi-annual performance briefing.
R&D investment for January-June 2026 was 731 million yuan.
The company is advancing R&D in digestive metabolism, cardiovascular and cerebrovascular, cold and respiratory, and neuropsychiatric therapeutic areas.
What to watch next
Further disclosures on specific product candidates and milestones from the company's innovation pipeline.
Any additional details from the full PDF briefing document referenced in the announcement.